Dallas, TX -- (SBWIRE) -- 01/07/2013 -- The market for kinase inhibitors is heating up. The newer segment has shown strong growth throughout the 2000s with average annual increases of nearly 17%. Although the market is becoming more established and several billion dollar drugs have emerged this segment has enormous room for growth. The potential market is expected to grow to reach almost $20 billion worldwide within the next five years. Several factors continue to influence the double-digit growth this market has experienced, including the continued success of targeted therapy in cancer treatment, rising incidence of cancer, and increased cost for newly approved therapies in the advanced treatment area.
This market report only includes estimates and forecasts for the kinase inhibitor market for cancer indications. The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar and unit sales for each product.
The report (http://www.reportsnreports.com/reports/213315-the-next-wave-in-cancer-treatment-kinase-inhibitors.html) includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.
Buy your copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=213315. Alternatively, Request A Sample @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=213315 to help make a purchase decision.
This research on the next wave in cancer treatment on kinase inhibitors is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including:
It indicates that cancer affects between 12 and 13 million people worldwide each year, and it is expected to increase to 16 million each year by 2020. Worldwide, approximately 24 million people are living with cancer and nearly 8 million people die each year. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to an 80% death rate for cancer patients in underdeveloped countries.
Manufacturers of cancer therapeutics designed to counter this trends are primarily U.S. and European companies, although a number of Japanese companies have become significant in the marketplace in the past fifteen years. AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer and Roche are among the companies profiled in this report.
Read comprehensive Table of Contents for the report @ http://www.reportsnreports.com/reports/213315-the-next-wave-in-cancer-treatment-kinase-inhibitors.html. Contact firstname.lastname@example.org for further information.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)